# Ideal Versus Actual Body Weight for Dosage of Sugammadex in Patients With Body Mass Index Less Than 18.5: A Randomized Controlled Trial

**Authors:** Hanae Sato, Tsukasa Uesaka, Takahiro Suzuki, Hajime Iwasaki

PMC · DOI: 10.7759/cureus.102536 · Cureus · 2026-01-29

## TL;DR

This study compared sugammadex dosing based on actual versus ideal body weight in underweight patients and found no significant difference in recovery time.

## Contribution

The study is the first to evaluate sugammadex dosing in underweight patients using actual versus ideal body weight.

## Key findings

- No significant difference in recovery time between actual and ideal body weight dosing groups.
- 32 underweight patients were analyzed for sugammadex recovery time from deep neuromuscular block.

## Abstract

Introduction: To date, no study has evaluated the appropriate sugammadex dose in underweight patients. Therefore, we aimed to compare time to recovery from deep neuromuscular block after administration of sugammadex based on either actual or ideal body weight in patients with a body mass index (BMI) of less than 18.5 kg/m2.

Methods: Patients with a BMI < 18.5 kg/m2 who underwent elective surgery under general anesthesia were enrolled. Anesthesia was induced and maintained with total intravenous anesthesia. Train-of-four (TOF) responses were monitored at the abductor digiti minimi muscle using electromyography following administration of rocuronium 0.6-0.9 mg/kg. An additional dose of rocuronium 0.2 mg/kg was administered to maintain deep neuromuscular block. When the post-tetanic count reached 1 or 2, sugammadex 4 mg/kg was administered, calculated based on either actual or ideal body weight. The primary outcome was the time from sugammadex administration to a TOF ratio ≥ 90%. Data were analyzed using the unpaired t-test, with statistical significance defined as p < 0.05.

Results: A total of 32 patients were included in the analysis. The difference between the actual and ideal body weight groups was not statistically significant (185.6 ± 89.5 s vs 147.3 ± 71.0 s; p = 0.19).

Conclusion: There was no significant difference in sugammadex recovery time from deep neuromuscular block between dosing based on actual body weight and dosing based on ideal body weight in underweight patients.

## Linked entities

- **Chemicals:** sugammadex (PubChem CID 6918585), rocuronium (PubChem CID 441290)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CST7 (cystatin F) [NCBI Gene 8530] {aka CMAP}
- **Diseases:** neuromuscular disease (MESH:D009468), postoperative (MESH:D019106), allergic reactions (MESH:D004342), eating disorders (MESH:D001068), Low (MESH:D009800), underweight (MESH:D013851), PTC (MESH:D009845), aspiration pneumonia (MESH:D011015), cardiac output (MESH:D002303), malnutrition (MESH:D044342), TOF (MESH:D000095027), airway obstruction (MESH:D000402), hypoalbuminemia (MESH:D034141), hypoxic (MESH:D002534), obese (MESH:D009765), deep neuromuscular block (MESH:D055191), pharyngeal dysfunction (MESH:D010608), airway muscle weakness (MESH:D018908), pulmonary complications (MESH:D008171), sarcopenia (MESH:D055948)
- **Chemicals:** creatinine (MESH:D003404), Sugammadex (MESH:D000077122), carbon dioxide (MESH:D002245), rocuronium (MESH:D000077123), vecuronium (MESH:D014673), steroidal (-), neostigmine (MESH:D009388), remifentanil (MESH:D000077208), propofol (MESH:D015742), fentanyl (MESH:D005283), lithium (MESH:D008094), aminoglycoside (MESH:D000617), gamma-cyclodextrin (MESH:C023792)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951408/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951408/full.md

---
Source: https://tomesphere.com/paper/PMC12951408